CTLA4 and neoplasm: Across studies, cirAEs were more frequent with regimens containing combinations of ICIs and in melanoma compared to other tumor types, highlighting the impact of new and more frequently used combination regimens, such as that of ICI and anti-angiogenic drugs or dual checkpoint blockade with CTLA-4 agents.